Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry

The characteristics, tolerability, and outcomes in patients with heart failure (HF) who are treated with sacubitril/valsartan remain unclear in Japan. We conducted a nationwide multicenter study to evaluate the features and outcomes of patients newly prescribed sacubitril/valsartan for the managemen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology 2024-08, Vol.84 (2), p.133-140
Main Authors: Matsumoto, Shingo, McMurray, John J.V., Nasu, Takahito, Ishii, Shunsuke, Kagiyama, Nobuyuki, Kida, Keisuke, Fujimoto, Wataru, Kikuchi, Atsushi, Ijichi, Takeshi, Shibata, Tatsuhiro, Ikeda, Takanori, Kanaoka, Koshiro
Format: Article
Language:English
Subjects:
Adverse event
Aged
Aged, 80 and over
Aminobutyrates - administration & dosage
Aminobutyrates - adverse effects
Angioedema - chemically induced
Angiotensin Receptor Antagonists - administration & dosage
Angiotensin Receptor Antagonists - adverse effects
Asia
Biphenyl Compounds
Drug Combinations
East Asian People
Female
Glomerular Filtration Rate
Heart Failure
Heart failure with preserved ejection fraction
Heart failure with reduced ejection fraction
Humans
Hyperkalemia - chemically induced
Hyperkalemia - epidemiology
Hypotension - chemically induced
Japan - epidemiology
Male
Middle Aged
Registries
Sacubitril/valsartan
Stroke Volume
Tetrazoles - administration & dosage
Tetrazoles - adverse effects
Valsartan - adverse effects
Withholding Treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The characteristics, tolerability, and outcomes in patients with heart failure (HF) who are treated with sacubitril/valsartan remain unclear in Japan. We conducted a nationwide multicenter study to evaluate the features and outcomes of patients newly prescribed sacubitril/valsartan for the management of HF. We analyzed adverse events (AEs) related to sacubitril/valsartan at 3 months, which were defined as hypotension, worsening renal function, hyperkalemia, and angioedema. Additionally, the association between AEs and outcomes was examined. Among 993 patients, the mean age was 70 years and 291 (29.3 %) were female, and 22.8 % had left ventricular ejection fraction ≥50 %. Of them, 20.8 % had systolic blood pressure (sBP)
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2023.11.005